13 completed. 13 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 13 |
| Phase 2 | 6 | Completed 6 |
Follow Electrocardiogram: new trials by email Literature Review of Electrocardiogram trials Research Report on Electrocardiogram
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152 - Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2023-04-05 | 2026-02-23 |
| Study of Codivir in Patients With COVID-19 Covidir injections, One Step Test, IgM and IgG dosage - Covid19 | Phase 1 | Completed | Code Pharma | 12 | 2021-03-29 | 2021-11-02 |
| Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies Romidepsin, Lenalidomide, CC-486 (5-azacitidine) - Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2020-12-17 | 2026-10-14 |
| HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers PRGN-2009, M7824, EKG - HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 39 | 2020-08-11 | 2026-08-18 |
| M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers M7824, Topotecan, Temozolomide - Carcinoma, Small Cell, Lung Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2018-09-11 | 2025-05-09 |
| Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) Durvalumab, Vicineum, Acetaminophen - Urinary Bladder Neoplasms | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2018-06-07 | 2026-10-27 |
| Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) M7824, N-803, MVA-BN-Brachyury - Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 59 | 2018-05-01 | 2025-09-30 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 54 | 2018-03-26 | 2025-06-04 |
| Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers rhIL-15, Ipilimumab, Nivolumab - Metastatic Solid Tumors, Treatment-Refractory Cancers | Phase 1 | Completed | National Cancer Institute (NCI) | 31 | 2018-02-05 | 2025-12-18 |
| E7 TCR T Cells for Human Papillomavirus-Associated Cancers E7 TCR cells, Aldesleukin, Fludarabine - Papillomavirus Infections, Cervical Intraepithelial Neoplasia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 224 | 2017-01-27 | 2026-03-09 |
| Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Rituximab, Conditioning chemotherapy, TMS - Myelodysplastic Syndromes, Hodgkin's Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 34 | 2015-09-24 | 2025-09-30 |
| Oral Nifedipine to Treat Iron Overload Nifedipine, Phlebotomy, Urinalysis - Thalassemia, Iron Overload | Phase 1 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 6 | 2008-06-20 | 2017-07-02 |
| Improvement of Use Dependent Plasticity in Chronic Stroke Patients Electrocardiogram - Healthy, Cerebrovascular Accident | Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 48 | 2003-11-06 | 2017-07-02 |
Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Carcinoma in Situ (2) · Anus Neoplasms (1) · Burkitt Lymphoma (1) · COVID-19 (1) · Carcinoma, Small Cell (1) · Coronavirus Infections (1) · Hematologic Neoplasms (1) · Hemochromatosis (1) · Hodgkin Disease (1) · Iron Overload (1) · Leukemia (1) · Leukemia, B-Cell (1) · Lung Neoplasms (1)
National Cancer Institute (NCI) (10) · Code Pharma (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
United States (12) · Brazil (1)
Alain Mina, M.D. (1) · Anish Thomas, M.D. (1) · Charalampos Floudas, M.D. (1) · Christopher J Melani, M.D. (1) · Eynat Finkelshtein (1) · James L Gulley, M.D. (1) · Jibran Ahmed, M.D. (1) · Nirali N Shah, M.D. (1) · Raju Chelluri, M.D. (1) · Samuel Ng, M.D. (1) · Scott M Norberg, D.O. (1)
PMID 30227893, PMID 32508818, PMID 33558725, PMID 33602696, PMID 34687939, PMID 34889384, PMID 35605184, PMID 37486616, PMID 37882668, PMID 37975597, PMID 38376944, PMID 40116923, PMID 40331908, PMID 41779512, PMID 42248607, PMID 42498485, PMID 42820295